Health analytics

Obesity

We work closely with pharmaceutical companies developing or marketing obesity treatments to craft strategies and generate evidence that drives positive commercial and access outcomes in the challenging obesity treatment market.

Obesity is a worldwide epidemic

Its prevalence is increasing at an alarming rate across the globe. Obesity can also lead to many obesity-related complications including heart disease, stroke, liver disease and type 2 diabetes. This imposes a substantial burden on individuals, healthcare systems, and societies at large.

Notwithstanding this growing crisis, the pharmaceutical landscape for obesity treatment is evolving rapidly. However, despite the growing body of evidence supporting these treatments, many payers are yet to fully recognise their value, creating challenges for life sciences companies in securing favourable market access.

The direct medical costs associated with obesity-related comorbidities and the indirect costs due to reduced productivity are staggering, running into billions of dollars annually worldwide. Despite the significant health and economic burden of obesity, payers remain sceptical about the value of pharmaceutical interventions as the evidence to demonstrate this is currently limited.

This creates a complex environment for market access, requiring nuanced strategies to demonstrate the full value of obesity medications. As the market becomes more crowded, differentiation and clear value proposition communication become crucial for success.

Strategic value propositions for obesity treatments

We support pharmaceutical companies in navigating obesity treatment market challenges, from ensuring robust clinical development programs to creating compelling value narratives and real-world evidence that resonates with payers and HTA bodies. Our approach is tailored to specific markets, patient populations, and competitor landscapes, always with an eye on maximising commercial potential.

Specifically, we help our pharmaceutical clients succeed in the obesity treatment market in a number of ways:

Developing comprehensive commercial strategies that align clinical development, pricing, and market access approaches for optimal positioning in the evolving obesity landscape
Crafting evidence generation strategies and generating real-world evidence that addresses payer concerns and demonstrates the full value of obesity treatments
Employing advanced analytics and economic modelling to demonstrate the long-term holistic benefits of obesity treatments, including healthcare cost offsets and productivity gains
Supporting market access strategies that effectively communicate value to payers, taking into account the unique challenges and opportunities in the obesity treatment space

We leverage our deep understanding of the global payer landscape and obesity treatment market to help clients navigate complex reimbursement environments. Our work empowers clients to develop compelling value propositions, engage effectively with stakeholders, and ultimately achieve commercial success in an increasingly competitive market.

By partnering with LCP Health Analytics, pharmaceutical companies can position themselves at the forefront of this market, improving patient access to innovative therapies whilst achieving commercial outcomes.